je.st
news
Former Biogen exec to lead Newton biotech, Chiasma
2015-03-16 21:21:07| Biotech - Topix.net
A longtime pharmaceutical executive who oversaw the launch of Biogen Idec's first multiple sclerosis drug, Avonex, has been named CEO of a privately held Newton biotech. Chiasma Inc., which recently raised $70 million in Series E financing and last week told the Boston Business Journal that it's in the process of looking for a new, larger headquarters in either Newton or Cambridge, today named Mark Leuchtenberger as its president and CEO.
Tags: lead
newton
biotech
exec
Category:Biotechnology and Pharmaceuticals